A Phase I Trial and In Vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

Por Ma, Tian, Fuld, Alexander D., Rigas, James R., Hagey, Anne E., Gordon, Gary B., Dmitrovsky, Ethan, Dragnev, Konstantin H.
Publicado em 2012

Recommended changes to oncology clinical trial design: Revolution or evolution?

Por Ratain, Mark J., Humphrey, Rachel W., Gordon, Gary B., Fyfe, Gwen, Adamson, Peter C., Fleming, Thomas R., Stadler, Walter M., Berry, Donald A., Peck, Carl C.
Publicado em 2007

Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial

Por Elmets, Craig A., Viner, Jaye L., Pentland, Alice P., Cantrell, Wendy, Lin, Hui-Yi, Bailey, Howard, Kang, Sewon, Linden, Kenneth G., Heffernan, Michael, Duvic, Madeleine, Richmond, Ellen, Elewski, Boni E., Umar, Asad, Bell, Walter, Gordon, Gary B.
Publicado em 2010

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751

Por Innocenti, Federico, Ramírez, Jacqueline, Obel, Jennifer, Xiong, Julia, Mirkov, Snezana, Chiu, Yi-Lin, Katz, David A., Carr, Robert A., Zhang, Wei, Das, Soma, Adjei, Araba, Moyer, Ann M., Chen, Pei Xian, Krivoshik, Andrew, Medina, Diane, Gordon, Gary B., Ratain, Mark J., Sahelijo, Leonardo, Weinshilboum, Richard M., Fleming, Gini F., Bhathena, Anahita
Publicado em 2013

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Por Seymour, John F, Ma, Shuo, Brander, Danielle M, Choi, Michael Y, Barrientos, Jacqueline, Davids, Matthew S, Anderson, Mary Ann, Beaven, Anne W, Rosen, Steven T, Tam, Constantine S, Prine, Betty, Agarwal, Suresh K, Munasinghe, Wijith, Zhu, Ming, Lash, L Leanne, Desai, Monali, Cerri, Elisa, Verdugo, Maria, Kim, Su Young, Humerickhouse, Rod A, Gordon, Gary B, Kipps, Thomas J, Roberts, Andrew W
Publicado no Lancet Oncol (2017)